Eli Lilly and CompanyvsNuvectis Pharma

LLY and NVCT stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,347.11

Value $1.27T

-0.30%
LLY's page

NVCT

Nuvectis Pharma, Inc.

$19.39

Value $667M

-4.44%
NVCT's page

Eli Lilly and Company (LLY) has a market value of $1.27T and Nuvectis Pharma (NVCT) $667M. Over the last year, with dividends, LLY moved +29.1% and NVCT +224.8%. Dividend yield: LLY 0.47%, NVCT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.27T

    NVCT$667M

    LLY is 1,906 times NVCT

  • Revenue, 12 months

    LLY$86.5B

    NVCT–

  • Net income, 12 months

    LLY$27.6B

    NVCT-$50M

  • Operating margin

    LLY–

    NVCT–

  • ROIC

    LLY35.5%

    NVCT-118.3%

    153.8 points apart

  • P/E

    LLY46.1

    NVCT–

  • Dividend yield

    LLY0.5%

    NVCT0.0%

    0.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+129.9%

NVCT+133.9%

100200300202420252026
Returns by period
PeriodLLYWith dividendsNVCTWith dividends
1 year since November 19, 2025+29.1%Price +28.3%+224.8%Price +224.8%
3 years since November 20, 2023+130.0%+32.0% a yearPrice +125.4%+133.9%+32.7% a yearPrice +133.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanyNVCTNuvectis Pharma

Valuation

LLYNVCT
Valuation
Price$1,347.11$19.39
Market value$1.27T$667M
Enterprise value (EV)$1.32T$526M
P/E46.1–
P/E, 5-year median49.9–
P/B31.65.3
EV/EBIT37.8–
Free cash flow yield1.6%–

Results and growth

LLYNVCT
Results and growth
Revenue, 12 months$86.5B–
Net income, 12 months$27.6B-$50M
Free cash flow, 12 months$19.7B-$40M
Earnings per share, 12 months$30.81-$1.89
Revenue growth, year on year44.7%–
Revenue growth a year, past+21.6%over 5 years–
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYNVCT
Margins and returns on capital
Gross margin83.6%–
Operating margin––
Net margin31.9%–
ROIC35.5%-118.3%
ROE88.6%-131.1%

Balance sheet

LLYNVCT
Balance sheet
Cash$4.9B$141M
Total debt$49.5B–
Net debt / EBITDA1.2–
Interest cover38.9×–

Dividends and buybacks

LLYNVCT
Dividends and buybacks
Dividend yield0.5%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%–
Shareholder yield0.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or NVCT

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or Nuvectis Pharma?

By market value, Eli Lilly and Company ($1.27T) is about 1,905.8 times Nuvectis Pharma ($667M), at today's prices.

How did LLY and NVCT stock do over the last 3 years?

Since November 20, 2023, LLY's price moved +125.4% and NVCT's +133.9%. With dividends: LLY +130.0% (+32.0% a year), NVCT +133.9% (+32.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or NVCT?

The dividend yield at today's price is 0.47% for Eli Lilly and Company and none for Nuvectis Pharma. Over the last twelve months they paid $6.34 and – per share.

Which is the better investment, Eli Lilly and Company or Nuvectis Pharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.